资讯

SurvivorNet on MSN7 小时
A Promising New Option For PIK3CA-Mutated Breast Cancer: What New Data On Inavolisib Could ...
Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.